Trial Profile
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses (2.5 µg, 10 µg, and 30 µg) of BI 1744 CL for 14 Days in Healthy Male and Female Volunteers (Double blind, Randomised, Placebo Controlled [at Each Dose Level] Study)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Olodaterol (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Boehringer Ingelheim
- 28 Jun 2014 New trial record